There are numerous radiation modalities for the definitive treatment of localized prostate cancer. Classic clinical trials have established the basic tenets of treatment approaches, and emerging data have generated new potential avenues of treatment that optimize the therapeutic ratio by increasing prostate cancer tumor control while minimizing treatment-related toxicity. In the definitive setting, the selection of the optimal radiation therapy approach depends largely on the appropriate up-front risk stratification of men with prostate cancer, with greater intensification of treatment and greater integration of multimodality therapies for men with higher-risk disease. Hormonal therapy should be selectively deployed based on prognostic information derived from the National Comprehensive Cancer Network risk group and biologic tumor aggressiveness informed by genomic classifiers. Moreover, treatment intensification and target volume delineation are increasingly informed by molecular imaging and multiparametric magnetic resonance imaging. Herein, we perform a critical appraisal of the literature focusing on the optimal selection of radiation therapy modality for localized prostate cancer. Collaboration among medical oncologists, surgeons, and radiation oncologists will be critical for coordinating evidence-based radiation therapies when clearly indicated and for supporting shared decision-making when the evidence is incomplete.
Clinical advances in hematology & oncology : H&O. 2023 Sep [Epub]
Luca F Valle, Amar U Kishan, Antonio Franco, Ting Martin Ma, John Nikitas, Matthew Farrell, Albert J Chang, Nicholas G Nickols, Michael L Steinberg
University of California Los Angeles, Department of Radiation Oncology, Los Angeles, California., California University of Science and Medicine, Colton, California., University of Washington, Department of Radiation Oncology, Seattle, Washington.